BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS - BriaCell Therapeutics (NASDAQ:BCTXW), BriaCell Therapeutics (NASDAQ:BCTX) : vimarsana.com

Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for similar patients reported in the literature*).32 out of 42 patients treated since 2022

Related Keywords

Miami , Florida , United States , Toronto , Ontario , Canada , Vancouver , British Columbia , United Kingdom , Philadelphia , Pennsylvania , San Antonio , Texas , Canadian , British , Carmen Calfa , Williamv Williams , Jules Abraham , Henryb Gonzalez Convention Center , Neither The Toronto Stock Exchange , Company Contact , Briacell Therapeutics Corp , University Of Miami Miller School Medicine , Clinical Research , Regulation Services Provider , Toronto Stock Exchange , Exchange Commission , Antonio Breast Cancer Symposium , Convention Center , Clinical Research Lead , Miami Miller School , Cancer Survivorship Program , Sylvester Comprehensive Cancer Center , Principal Clinical Investigator , Randomized Phase , Allogenic Human Cell Line , Antigen Presenting Activity , Heavily Pretreated Metastatic Breast , Poster Session , Thursday December , Immune Check Point , Overall Survival , Lymphocyte Ratio , Cancer Res , Annual Information Form , Briacell Therapeutics ,